Montgomery begins coverage of Valentis

Montgomery & Co., LLC equity research analysts Wade H. King and Shiv S. Kapoor are now covering Valentis, Inc., a development-stage biotechnology company targeting the large peripheral artery disease market. The company's lead product candidate, VLTS-934, is in phase 2b trials. Shares of the Burlingame, Calif.-based biotechnology company were up 16 cents, or 4.97%, at $3.43 on volume of 78,623 shares versus the three-month running average of 117,578 shares. (Nasdaq: VLTS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.